The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study
Ritonavir-boosted darunavir (DRV/r) and dolutegravir (DTG) are affected by induction of metabolizing enzymes and efflux transporters caused by rifampicin (RIF). This complicates the treatment of people living with HIV (PLWH) diagnosed with tuberculosis. Recent data showed that doubling DRV/r dose di...
Main Authors: | Calcagno, A. (Author), D'Avolio, A. (Author), De Nicolò, A. (Author), De Vivo, E. (Author), Di Perri, G. (Author), Ebrahim, I.-E (Author), Maartens, G. (Author), McIlleron, H. (Author), Motta, I. (Author), Orrell, C. (Author), Wiesner, L. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
NLM (Medline)
2022
|
Subjects: | |
Online Access: | View Fulltext in Publisher |
Similar Items
-
Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance
by: Eva Wolf, et al.
Published: (2021-09-01) -
A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data
by: Amedeo F. Capetti, et al.
Published: (2017-09-01) -
Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy
by: Kairoonisha Mahomed, et al.
Published: (2020-07-01) -
Pharmacokinetic interactions between rifampicin and efavirenz in HIV-TB coinfections
by: Yenny
Published: (2009-12-01) -
Pharmacokinetic interactions between rifampicin and efavirenz in HIV-TB coinfections
by: Yenny Yenny
Published: (2016-02-01)